

process. Accordingly, such information is afforded confidential treatment under exemption 8 of the Freedom of Information Act (FOIA), which protects information from disclosure that is contained in or related to the examination or supervision of a financial institution. 5 U.S.C. 552(b)(8). In addition, the information may also be kept confidential under exemption 4 of the FOIA, which protects trade secrets or confidential commercial or financial information. 5 U.S.C. 552(b)(4). In limited circumstances, aggregate data for multiple respondents, which does not reveal the identity of any individual respondent, may be released.

**Current actions:** On December 28, 2019, the Board published a notice in the **Federal Register** (83 FR 67285) requesting public comment for 60 days on the extension, with revision, of the FR 2052a. On September 12, 2018, the Board temporarily approved<sup>3</sup> certain revisions to the FR 2052a relating to the Economic Growth, Regulatory Relief, and Consumer Protection Act and the Board's related interim final rule amending the treatment of certain municipal obligations that are liquid and readily marketable as high quality liquid assets (HQLAs) under the LCR rule.<sup>4</sup> Specifically, the Board amended the Assets Category Table in Appendix III of the FR 2052a such that the description of the asset classification code "IG2-Q" is sufficiently inclusive of municipal obligations that may qualify as HQLAs under the LCR rule. The comment period for this notice expired on February 26, 2019. The Board did not receive any comments. The revisions will be implemented as proposed. Board of Governors of the Federal Reserve System, March 22, 2019.

**Michele Taylor Fennell,**

*Assistant Secretary of the Board.*

[FR Doc. 2019-05841 Filed 3-26-19; 8:45 am]

**BILLING CODE P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the

provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended, and the Determination of the Chief Operating Officer, CDC, pursuant to Public Law 92-463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—RFA-IP19-004, Network of Forecasting Centers to Improve Forecast Accuracy and Communication for Seasonal and Pandemic Influenza.

**Date:** May 22, 2019.

**Time:** 10:00 a.m.–5:00 p.m., (EDT).

**Place:** Teleconference, Centers for Disease Control and Prevention, Room 1080, 8 Corporate Square Blvd., Atlanta, GA 30329.

**Agenda:** To review and evaluate grant applications.

#### **FOR FURTHER INFORMATION CONTACT:**

Gregory Anderson, M.S., M.P.H., Scientific Review Officer, CDC, 1600 Clifton Road NE, Mailstop E60, Atlanta, Georgia 30329, (404) 718-8833, [gca5@cdc.gov](mailto:gca5@cdc.gov).

The Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Sherri Berger,**

*Chief Operating Officer, Centers for Disease Control and Prevention.*

[FR Doc. 2019-05832 Filed 3-26-19; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Cancellation of Meeting: The Secretary's Advisory Committee on Human Research Protections

**AGENCY:** Office of the Assistant Secretary for Health, Office of the Secretary, Department of Health and Human Services.

**ACTION:** Notice.

**SUMMARY:** Pursuant to Section 10(a) of the Federal Advisory Committee Act, notice is hereby given that the meeting of the Secretary's Advisory Committee on Human Research Protections

(SACHRP), scheduled to occur March 27 and 28, 2019, at 6700B Rockledge Drive, Suite 1102, Bethesda MD 20892, has been cancelled. The **Federal Register** Notice announcing this meeting appeared March 11, 2019. The next meeting is scheduled for July 30 and 31, 2019.

**FOR FURTHER INFORMATION CONTACT:** Julia Gorey, J.D., Executive Director, SACHRP; U.S. Department of Health and Human Services, 1101 Wootton Parkway, Suite 200, Rockville, Maryland 20852; telephone: 240-453-8141; fax: 240-453-6909; email address: [SACHRP@hhs.gov](mailto:SACHRP@hhs.gov).

**SUPPLEMENTARY INFORMATION:** Under the authority of 42 U.S.C. 217a, Section 222 of the Public Health Service Act, as amended, SACHRP was established to provide expert advice and recommendations to the Secretary of Health and Human Services, through the Assistant Secretary for Health, on issues and topics pertaining to or associated with the protection of human research subjects.

Dated: March 19, 2019.

**Julia G. Gorey,**

*Executive Director, Secretary's Advisory Committee on Human Research Protections.*

[FR Doc. 2019-05801 Filed 3-26-19; 8:45 am]

**BILLING CODE 4150-36-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; PAR-17-123: Biomarkers for Diabetes, Digestive, Kidney and Urologic Diseases using NIDDK Biorepository Samples (R01).

**Date:** May 6, 2019.

**Time:** 12:00 p.m. to 3:00 p.m.

<sup>3</sup> See 83 FR 46163 (September 12, 2018).

<sup>4</sup> See 83 FR 44451 (August 31, 2018).